SG Americas Securities LLC Has $2.26 Million Stake in Intellia Therapeutics, Inc. $NTLA

SG Americas Securities LLC raised its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 239.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 131,070 shares of the company’s stock after acquiring an additional 92,485 shares during the period. SG Americas Securities LLC’s holdings in Intellia Therapeutics were worth $2,264,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Marex Group plc acquired a new stake in shares of Intellia Therapeutics in the 2nd quarter valued at $5,849,000. JPMorgan Chase & Co. boosted its position in Intellia Therapeutics by 73.0% in the second quarter. JPMorgan Chase & Co. now owns 940,483 shares of the company’s stock valued at $8,822,000 after buying an additional 396,858 shares in the last quarter. Schroder Investment Management Group grew its stake in Intellia Therapeutics by 1,593.4% during the second quarter. Schroder Investment Management Group now owns 406,425 shares of the company’s stock worth $3,812,000 after buying an additional 382,425 shares during the last quarter. Vestmark Advisory Solutions Inc. increased its holdings in shares of Intellia Therapeutics by 104.7% during the second quarter. Vestmark Advisory Solutions Inc. now owns 638,342 shares of the company’s stock worth $5,988,000 after buying an additional 326,460 shares in the last quarter. Finally, Armistice Capital LLC raised its stake in shares of Intellia Therapeutics by 78.6% in the second quarter. Armistice Capital LLC now owns 650,000 shares of the company’s stock valued at $6,097,000 after acquiring an additional 286,000 shares during the last quarter. 88.77% of the stock is owned by institutional investors.

Intellia Therapeutics Stock Up 2.7%

Shares of NTLA stock opened at $11.74 on Wednesday. The firm has a market cap of $1.36 billion, a price-to-earnings ratio of -2.75 and a beta of 2.05. Intellia Therapeutics, Inc. has a 12 month low of $5.90 and a 12 month high of $28.25. The stock has a 50-day moving average price of $9.40 and a 200 day moving average price of $12.75.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, November 6th. The company reported ($0.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.02) by $0.10. The company had revenue of $13.78 million for the quarter, compared to analyst estimates of $14.12 million. Intellia Therapeutics had a negative net margin of 774.94% and a negative return on equity of 57.01%. The company’s revenue for the quarter was up 51.6% on a year-over-year basis. During the same quarter last year, the firm earned ($1.34) EPS. Sell-side analysts predict that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Wall Street Zen upgraded Intellia Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Wells Fargo & Company lowered their target price on Intellia Therapeutics from $17.00 to $12.00 and set an “equal weight” rating for the company in a research note on Friday, November 7th. Wedbush cut their price target on Intellia Therapeutics from $9.00 to $7.00 and set a “neutral” rating for the company in a report on Friday, November 7th. William Blair downgraded shares of Intellia Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, October 27th. Finally, Bank of America lowered their price objective on shares of Intellia Therapeutics from $36.00 to $30.00 and set a “buy” rating for the company in a research report on Monday, October 27th. Nine research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, Intellia Therapeutics currently has an average rating of “Hold” and an average price target of $17.00.

Insiders Place Their Bets

In other news, EVP Birgit C. Schultes sold 8,508 shares of the firm’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $78,358.68. Following the transaction, the executive vice president directly owned 98,533 shares in the company, valued at $907,488.93. This trade represents a 7.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO John M. Leonard sold 34,146 shares of Intellia Therapeutics stock in a transaction on Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $314,484.66. Following the sale, the chief executive officer directly owned 1,013,339 shares of the company’s stock, valued at approximately $9,332,852.19. This trade represents a 3.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 53,051 shares of company stock valued at $488,600. Company insiders own 3.10% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.